Navigation Links
Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy
Date:5/29/2009

Abstract # 25670

ORLANDO, Fla., May 29 /PRNewswire-USNewswire/ -- The American Society of Clinical Oncology (ASCO) has selected new breast cancer research conducted at the Barbara Ann Karmanos Cancer Institute in Detroit for posting on ASCO's Web site. Karmanos' potentially ground-breaking findings identify a promising new therapeutic target for aggressive hormone receptor negative breast cancer tumors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO)

The research appears at www.ASCO.org and www.jco.org and is entitled "Enhancer of Zeste Homologue 2 (EZH-2) expression in breast cancer: a novel marker and potential target."

Karmanos scientists tested 84 cases of hormone receptor negative human breast carcinomas and discovered that the protein EZH-2 was expressed in 74 percent of those cases. Hormone receptor negative breast carcinoma is considered an aggressive cancer and one that is hard to treat. The finding suggests that EZH-2 could be an important therapeutic target in this patient population.

"We were interested in looking at a new target," said Zeina Nahleh, M.D., co-director of the Breast Oncology Multidisciplinary Team at Karmanos Cancer Institute and assistant professor of medicine in hematology and oncology at Wayne State University School of Medicine. "We wanted to see how much expression of the protein was present. We were surprised that 74 percent of tumors expressed that EZH-2 protein."

Sixty-one samples that researchers used were triple negative breast cancer cases and 23 cases were HER-2/neu positive. Scientists found that the increased expression of EZH-2 meant an increase in tumor size and an increase in lymph node metastasis.

Dr. Nahleh said that increased identification of proteins in these aggressive forms of breast cancer is needed to develop better treatments. The discovery of the high rate of EZH-2 protein expression in breast cancer cases opens up a new avenue in doing just that.

"We are extremely excited about this discovery," she said. "This is amazing work. In the future, this could be a target for therapy."

The identification of EZH-2 represents just the first step in the mission to find more proteins that cause deadly breast cancer tumors and assess them for possible therapeutic targets. There is much work ahead, according to Dr. Nahleh.

"The ground-breaking work will come if we can identify a specific method to target this EZH-2 protein and show that this approach would lead to meaningful clinical results," she said. "We have to go back and look at survival rates. We have to consider years of follow-up work and we have to look at other associated factors.

"This will hopefully lead to new targeted therapy strategies based on our new understanding of the biology of cancer."

Fellow investigators include Sudeshna Bandyopadhyay, M.D., of Wayne State University School of Medicine; Rouba Ali Fehmi, M.D., of the Karmanos Cancer Institute and Wayne State University School of Medicine; Haitham Arabi, M.D., resident of the Wayne State University School of Medicine's Department of Pathology ; Wael Sakr, M.D., of the Karmanos Cancer Institute and Wayne State University School of Medicine; Adnan Munkarah, M.D., of the Henry Ford Health System in Detroit; and Michael Kruger, statistical analyst with Wayne State University School of Medicine's Department of Obstetrics and Gynecology.

Dr. Nahleh noted that the discovery of a potential therapeutic target wouldn't be possible without the laboratory and clinical breast cancer research at Karmanos and its collaborative partnerships.

"I think this discovery highlights the importance of multidisciplinary work in oncology between clinical and scientific researchers," she said. "This is what Karmanos is all about."

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
2. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
3. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
4. Brain Stem Cells Can Be Awakened, Say Schepens Scientists
5. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
6. Scientists Reveal Roadmap to Brain Health That Can Be Passed Down to Future Generations: Exercise, Omega-3, Folic Acid, Vitamin B6, and Vitamin B12
7. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
8. Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
9. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
10. Scientists Unmask Genetic Markers Associated With Psoriasis
11. Scientists Discover Why Teeth Form in a Single Row
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
Breaking Medicine News(10 mins):